Since 2018, the use of robot-assisted thoracoscopic surgery (RATS) has steadily increased in the field of thoracic surgery after insurance coverage has been gained. This trend is expected to continue, with the number of RATSprocedures likely to rise even further. Our department began performing RATS for mediastinal tumors in April2020 and expanded to include lung malignancies in April 2022. The primary advantage of RATS is its ability toperform precise surgical operations, making it highly useful for procedures such as complex segmentectomies andsurgeries involving incomplete fissures. However, the main drawback of RATS is its high cost. Safety is also aconcern, but our department has successfully implemented RATS safely. The long-term outcomes of RATS are notyet fully understood, so we plan to accumulate cases and investigate the safety and efficacy of RATS further
